Matching Scores and Combination Therapy May Lead to Improved Outcomes
An observational study of 180 patients with solid advanced cancers found that matching patients with drugs targeting their genomic anomalies was associated with better outcomes. Further, when a “Matching Score” that integrated the number of matches and number of alterations was used, the Matching Score was predictive of longer survival. The study also suggested that matched combination therapy may have a stronger association with survival for patients with multiple molecular alterations than monotherapy.
Link to article in Molecular Cancer Therapy